NASDAQ · Biotechnology · USD
Greenwich LifeSciences, Inc. (GLSI) Stock Analysis
Greenwich LifeSciences, Inc. (GLSI) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
GLSI Key Statistics
As of Oct 21, 2026Trading
- Open
- $16.41
- Previous Close
- $16.24
- Day's Range
- 16.16–16.67
- 52-Week Range
- 7.78–34.10
- Volume
- 81.96K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 1.46
Valuation
- Market Cap
- $243.22M
- P/E Ratio
- unprofitable
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −1.53
Financials (FY)
- Revenue (FY)
- $0.00
- Net Income (FY)
- −$19.36M
- Shares Outstanding
- 14.68M
- 1-Year Return
- +80.90%
Dividend and dates
- Earnings Date
- November 12, 2026estimated
- Avg Volume
- 128.31K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, GLSI closed at $16.57, +80.90% over 1 year.
Greenwich LifeSciences, Inc. (GLSI) has a market capitalization of $243.22M.
In fiscal 2025, GLSI reported revenue of $0.00.
GLSI Stock Return by Calendar Year
Greenwich LifeSciences, Inc. (GLSI) return since Sep 2020: what $10,000 became
- 1 year
- $10,000 $18,090
- +80.90%
- 5 years
- $10,000 $4,660
- −53.40%
- Since Sep 2020
- $10,000 $33,140
- +231.40%
If you had invested $10,000 in Greenwich LifeSciences, Inc. (GLSI) at the close on September 25, 2020, the earliest close on record here, it would have been worth $33,140 at the close on October 21, 2026: +231.40% in total, +21.82% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −21.13% |
| 2025 | +87.09% |
| 2024 | +6.75% |
| 2023 | −30.79% |
| 2022 | −37.53% |
| 2021 | −33.29% |
| 2020 (partial year) | +629.40% |
As of October 21, 2026.
GLSI Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $0.00 | −$19.36M | — |
| 2024 | $0.00 | −$17.41M | — |
| 2023 | $0.00 | −$8.89M | — |
| 2022 | $0.00 | −$7.83M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $0.00 | — | −$19.45M | −$19.36M | — |
| 2024 | $0.00 | — | −$17.64M | −$17.41M | — |
| 2023 | $0.00 | — | −$9.33M | −$8.89M | — |
| 2022 | $0.00 | — | −$8.04M | −$7.83M | — |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
Recent News
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B